Surrozen (NASDAQ:SRZN) Posts Earnings Results, Misses Expectations By $9.92 EPS

Surrozen (NASDAQ:SRZN) announced its quarterly earnings data on Monday. The company reported ($11.02) EPS for the quarter, missing analysts’ consensus estimates of ($1.10) by ($9.92), FiscalAI reports.

Surrozen Trading Up 3.2%

Shares of SRZN traded up $1.00 during mid-day trading on Monday, reaching $32.00. The company had a trading volume of 120,850 shares, compared to its average volume of 258,997. Surrozen has a fifty-two week low of $11.66 and a fifty-two week high of $37.83. The firm has a fifty day simple moving average of $24.94 and a 200-day simple moving average of $25.24. The stock has a market cap of $371.52 million, a price-to-earnings ratio of -0.79 and a beta of 0.51.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on SRZN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, October 15th. William Blair assumed coverage on shares of Surrozen in a research note on Thursday, August 20th. They set an “outperform” rating and a $51.00 price objective for the company. Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. Finally, HC Wainwright reiterated a “buy” rating and set a $54.00 price objective (up from $44.00) on shares of Surrozen in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $48.33.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.